<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04690426</url>
  </required_header>
  <id_info>
    <org_study_id>PRV-101-001</org_study_id>
    <nct_id>NCT04690426</nct_id>
  </id_info>
  <brief_title>PROtocol for Coxsackievirus VaccinE in Healthy VoluNTteers</brief_title>
  <acronym>PROVENT</acronym>
  <official_title>A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of PRV-101, a Coxsackie Virus B (CVB) Vaccine, in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Provention Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Provention Bio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1, first-in-human, randomized, double-blind, placebo-controlled,&#xD;
      multiple-dose-escalation study to evaluate the safety, tolerability and immunogenicity of&#xD;
      PRV-101, a coxsackie virus B vaccine, in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thirty two healthy adult subjects will be enrolled into 2 dose cohorts (low-dose and&#xD;
      high-dose cohorts, 16 subjects per cohort) and will be randomized in a double-blind manner to&#xD;
      PRV-101 or placebo in a 3:1 ratio. Each subject will receive up to 3 administrations of the&#xD;
      study drug (PRV-101 or placebo) at 4-week intervals and will be followed for 24 weeks after&#xD;
      the final dose. Each cohort will start with a sentinel dosing group (2 subjects). Cohort 2&#xD;
      will commence after safety data from the first 2 doses from all Cohort 1 participants are&#xD;
      reviewed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (safety and tolerability)</measure>
    <time_frame>Throughout the 32 weeks of the study</time_frame>
    <description>Adverse events will be assessed by frequency and criteria for severity (mild, moderate or severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of neutralizing antibodies to coxsackie B virus (immunogenicity, efficacy)</measure>
    <time_frame>Days 1, 29, and 57 and Weeks 12 and 32</time_frame>
    <description>Proportion of responders (ie, those that seroconvert or have at least a 4-fold increase in neutralizing antibody titers to any of the coxsackie B virus strains as measured by plaque reduction assay using serial serum dilutions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titer of antibodies to coxsackie B virus (immunogenicity, efficacy)</measure>
    <time_frame>Days 1, 29 and 57 and weeks 12 and 32</time_frame>
    <description>Mean and peak geometric mean serum IgG titers of antibodies against any of the coxsackie B virus strains, measured by ELISA</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Viral; Infection, Coxsackie(Virus)</condition>
  <arm_group>
    <arm_group_label>Cohort 1, Low Dose, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Low dose of placebo by intramuscular injection, 3 doses at 4-week intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Low Dose, PRV-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose of PRV-101 by intramuscular injection, 3 doses at 4-week intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, High Dose, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>High dose of placebo by intramuscular injection, 3 doses at 4-week intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, High Dose, PRV-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose of PRV-101 by intramuscular injection, 3 doses at 4-week intervals</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRV-101</intervention_name>
    <description>Coxsackie Virus B vaccine</description>
    <arm_group_label>Cohort 1, Low Dose, PRV-101</arm_group_label>
    <arm_group_label>Cohort 2, High Dose, PRV-101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Cohort 1, Low Dose, Placebo</arm_group_label>
    <arm_group_label>Cohort 2, High Dose, Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults, males and females, ages 18 to 45 yrs, with BMI 19 to 30 kg/m2&#xD;
&#xD;
          -  Women of childbearing potential must have negative pregnancy test and agree to use an&#xD;
             acceptable method of highly effective contraceptive&#xD;
&#xD;
          -  Men must either have a vasectomy or agree to use highly effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior or current clinically significant medical illness or disorder&#xD;
&#xD;
          -  Has celiac disease or type 1 diabetes or related autoantibodies&#xD;
&#xD;
          -  Has active acute or chronic/latent infection, or history of recent serious infection&#xD;
&#xD;
          -  Recent acute illness or recent major illness, hospitalization or surgery&#xD;
&#xD;
          -  Recent history of alcohol or drug abuse&#xD;
&#xD;
          -  Received an experimental antibody or biologic therapy in last 6 months&#xD;
&#xD;
          -  Received live, inactivated or subunit virus vaccine or a bacterial vaccine within last&#xD;
             4 weeks&#xD;
&#xD;
          -  Intolerance or hypersensitivity to vaccines or vaccine components or has a drug or&#xD;
             food allergy or allergic disease requiring medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Scientific Officer</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRST Oy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francisco Leon, CSO, MD, PhD</last_name>
    <phone>908-356-0471</phone>
    <email>info@proventionbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chief Medical Officer</last_name>
    <phone>908-356-0514</phone>
    <email>info@proventionbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Research Services Turku (CRST) Oy</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CSO</last_name>
      <phone>+358 2 420 64 700</phone>
      <email>info@crst.fi</email>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>https://www.crst.fi/tutkimukset/provention-tutkimus.html</url>
    <description>Study website</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coxsackie Virus B, vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Coxsackievirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

